Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme

1. Miehlke, S.
2. Schlag, C.
3. Lucendo, A.J.
4. Biedermann, L.
5. Vaquero, C.S.
6. Schmoecker, C.
7. Hayat, J.
8. Hruz, P.
9. Ciriza de Los Rios, C.
10. Bredenoord, A.J.
11. Vieth, M.
12. Schoepfer, A.
13. Attwood, S.
14. Mueller, R.
15. Burrack, S.
16. Greinwald, R.
17. Straumann, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1002/UEG2.12220 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus